Enhance transfer function of tamoxifen on the estrogen receptor α36 in the breast cancer patients
10.13699/j.cnki.1001-6821.2018.09.010
- VernacularTitle:他莫昔芬对乳腺癌患者的雌激素受体α36的增强转移作用
- Author:
Jian-Kui WANG
1
;
Ming LI
;
Xiao-Juan YANG
;
Juan DU
;
Shao-Qiang ZHOU
Author Information
1. 昆明医科大学第三附属医院、云南省肿瘤医院乳腺外二科
- Keywords:
tamoxifen;
breast cancer stem cell;
estrogen receptor α36
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(9):1042-1044
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of tamoxifen on the estrogen receptor α36 (ERα36) in breast cancer patients and its mechanism.Methods The patients with breast cancer treated from January 2010 to January 2015 were randomly selected.Among the 100 patients treated with tamoxifen,20 mg · d-1 tamoxifen was given daily for the treatment group.And receive starch slices of 100 patients,as the control group.After 5 d of treatment,ERα36 cells were sorted out of the breast cancer suppressor cell population of the two groups by fluorescence activated cell sorting device from the ERα36 membrane-targeting receptor.The expression of ERα36 was detected by immunohistochemistry.Then the proliferation and metastasis of ERα36 cells were compared between the two groups.Finally,combined with disease-free surial (DSF) and average no transfer surial (MFS) in two groups.Results The positive expression of ERα36 in treatment group and control group were 42,53 cases;the less than 2 cm in tumor size in the 2 group were 11,24 cases;comparison between two groups,the difference was statistically significant (all P ＜ 0.05).It indicating that the expression of ERα36 was associated with the deterioration of breast cancer cells.Of the treatment group of patients with 58 cases of metastatic cases,significantly higher than the control group of 42 cases,and the treatment group died in 28 cases,while the control group died in 19 cases,the difference was statistically significant between the 2 groups (all P ＜ 0.05).Multivariate regression analysis showed that tamoxifen treatment was negatively correlated with DFS and MFS in these patients.It indicating that compared with the absence of tamoxifen treatment,the prognosis of patients treated with tamoxifen was worse,and the mortality and metastasis were higher in patients treated with tafloxacin,the absence of metastatic survival of ERα36 tumors treated with tamoxifen was significantly shorter.Conclusion Selective tamoxifen will result in acquired and primary drug resistance in breast cancer patients,with significant side effects on ERα36 in patients with breast cancer.
